English A R, Girard D, Jasys V J, Martingano R J, Kellogg M S
Pfizer Central Research, Groton, Connecticut 06340.
J Med Chem. 1990 Jan;33(1):344-7. doi: 10.1021/jm00163a055.
Sulbactam (1) is a beta-lactamase inhibitor with limited oral bioavailability. Lipophilic double-ester prodrug sulbactam pivoxil (2) significantly improves the oral absorption of sulbactam, as does the mutual prodrug double ester sultamicillin (3). We have found that double-ester prodrugs of sulbactam terminating in a carboxyl group (8) also were effective oral-delivery vehicles in rats. Carboxyl-terminated double esters have several potential advantages over their nonionizable lipophilic counterparts, including water solubility, crystallinity, choice of salts for dosage forms, and formation of innocuous byproducts on hydrolysis.
舒巴坦(1)是一种口服生物利用度有限的β-内酰胺酶抑制剂。亲脂性双酯前药舒巴坦匹伐酯(2)显著提高了舒巴坦的口服吸收,相互前药双酯舒他西林(3)也是如此。我们发现,末端为羧基的舒巴坦双酯前药(8)在大鼠中也是有效的口服给药载体。与不可离子化的亲脂性对应物相比,羧基末端双酯具有几个潜在优势,包括水溶性、结晶性、剂型盐的选择以及水解时形成无害副产物。